Arovella Therapeutics (ASX:ALA)
ASX announcement history & article coverage
Transparent by design.
Announcments by Arovella Therapeutics (ASX:ALA) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notice under Section 708A
Notification of cessation of securities - ALA
Application for quotation of securities - ALA
First-In-Human Trial
Change of Director's Interest Notice
Turtle to Clinical Advisory Board&Fiorenza Lead Investigator
Notification of cessation of securities - ALA
Notification of cessation of securities - ALA
Final Director's Interest Notice x4
Arovella Presents at ISCT Conference in Dublin
Arovella Appoints Acting CEO
Arovella Therapeutics appoints Dr Nicole Van Der Weerden as Acting CEO following Dr Michael Baker's resignation
Board Refresh and CEO Resignation
Arovella Therapeutics announces CEO resignation and board refresh amid strategic review
Initial Director's Interest Notice x4
Appointment of 4x Non-Executive Directors
Quarterly Activities/Appendix 4C Cash Flow Report
Arovella’s IND accepted by FDA for ALA-101; clinical trial to start Q3 CY26 with $16.6M cash
Notification regarding unquoted securities - ALA
Notice Received Under Section 249D Withdrawn
Proposed issue of securities - ALA
Update Regarding Section 249D Notice
Arovella Presents Poster at AACR Annual Meeting
ALA Receives Additional R&D Tax Rebate of $0.28 Million